MEDNAX Stock Price, News & Analysis (NYSE:MD)

$23.00
-0.11 (-0.48 %)
(As of 09/22/2019 03:16 PM ET)
Today's Range
$22.9650
Now: $23.00
$23.49
50-Day Range
$20.53
MA: $21.87
$23.92
52-Week Range
$19.93
Now: $23.00
$47.71
Volume2.49 million shs
Average Volume864,928 shs
Market Capitalization$1.94 billion
P/E Ratio6.55
Dividend YieldN/A
Beta0.73
MEDNAX, Inc, together with its subsidiaries, provides newborn, anesthesia, maternal-fetal, radiology and teleradiology, pediatric cardiology, and other pediatric subspecialty physician services in the United States and Puerto Rico. It offers neonatal care services, such as clinical care to babies born prematurely or with complications within specific units at hospitals through neonatal physician subspecialists, neonatal nurse practitioners, and other pediatric clinicians; anesthesia and anesthesia subspecialty care services; and acute and chronic pain management services. Read More…

Industry, Sector and Symbol

Industry Hospitals
Sub-IndustryHealth Care Services
SectorMedical
CUSIP58502B10
Phone954-384-0175

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$3.65 billion
Cash Flow$4.8729 per share
Book Value$34.53 per share

Profitability

Net Income$268.62 million

Miscellaneous

Employees7,625
Market Cap$1.94 billion
Next Earnings Date11/7/2019 (Estimated)
OptionableOptionable

Receive MD News and Ratings via Email

Sign-up to receive the latest news and ratings for MD and its competitors with MarketBeat's FREE daily newsletter.


MEDNAX (NYSE:MD) Frequently Asked Questions

What is MEDNAX's stock symbol?

MEDNAX trades on the New York Stock Exchange (NYSE) under the ticker symbol "MD."

How were MEDNAX's earnings last quarter?

MEDNAX Inc (NYSE:MD) released its quarterly earnings results on Thursday, August, 1st. The company reported $0.89 earnings per share for the quarter, beating analysts' consensus estimates of $0.78 by $0.11. The business had revenue of $868.31 million for the quarter, compared to analysts' expectations of $868.71 million. MEDNAX had a negative net margin of 3.53% and a positive return on equity of 9.34%. The company's revenue was up .4% compared to the same quarter last year. During the same period last year, the business earned $1.07 EPS. View MEDNAX's Earnings History.

When is MEDNAX's next earnings date?

MEDNAX is scheduled to release their next quarterly earnings announcement on Thursday, November 7th 2019. View Earnings Estimates for MEDNAX.

What guidance has MEDNAX issued on next quarter's earnings?

MEDNAX issued an update on its third quarter earnings guidance on Thursday, August, 1st. The company provided earnings per share (EPS) guidance of $0.88 to $0.96 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $0.94.

What price target have analysts set for MD?

10 analysts have issued 1 year target prices for MEDNAX's shares. Their forecasts range from $19.00 to $40.00. On average, they expect MEDNAX's stock price to reach $28.5556 in the next twelve months. This suggests a possible upside of 24.2% from the stock's current price. View Analyst Price Targets for MEDNAX.

What is the consensus analysts' recommendation for MEDNAX?

10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for MEDNAX in the last year. There are currently 2 sell ratings, 5 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for MEDNAX.

Has MEDNAX been receiving favorable news coverage?

News headlines about MD stock have been trending somewhat negative this week, InfoTrie reports. The research group identifies negative and positive press coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. MEDNAX earned a news sentiment score of -1.3 on InfoTrie's scale. They also gave media headlines about the company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the stock's share price in the near future. View News Stories for MEDNAX.

Who are some of MEDNAX's key competitors?

What other stocks do shareholders of MEDNAX own?

Based on aggregate information from My MarketBeat watchlists, some companies that other MEDNAX investors own include Gilead Sciences (GILD), Chevron (CVX), Dominion Energy (D), Walt Disney (DIS), JPMorgan Chase & Co. (JPM), Boeing (BA), CVS Health (CVS), General Electric (GE), Merck & Co., Inc. (MRK) and Pfizer (PFE).

Who are MEDNAX's key executives?

MEDNAX's management team includes the folowing people:
  • Dr. Roger J. Medel, Co-Founder, CEO & Director (Age 72)
  • Mr. Joseph M. Calabro, Pres (Age 58)
  • Mr. Stephen D. Farber, Exec. VP & CFO (Age 49)
  • Mr. David A. Clark, Chief Operating Officer (Age 52)
  • Mr. Dominic J. Andreano, Sr. VP, Gen. Counsel & Sec. (Age 50)

Who are MEDNAX's major shareholders?

MEDNAX's stock is owned by many different of retail and institutional investors. Top institutional investors include BlackRock Inc. (9.73%), Vanguard Group Inc. (9.38%), Price T Rowe Associates Inc. MD (5.63%), D. E. Shaw & Co. Inc. (3.56%), P2 Capital Partners LLC (3.27%) and AQR Capital Management LLC (2.08%). Company insiders that own MEDNAX stock include Cesar L Alvarez, David A Clark, Dominic J Andreano, John C Pepia, Joseph M Calabro, Md Pascal J Goldschmidt, Michael Fernandez and Vivian Lopez-Blanco. View Institutional Ownership Trends for MEDNAX.

Which major investors are selling MEDNAX stock?

MD stock was sold by a variety of institutional investors in the last quarter, including Price T Rowe Associates Inc. MD, Wedge Capital Management L L P NC, First Trust Advisors LP, Natixis, Natixis, BlackRock Inc., Schroder Investment Management Group and Schroder Investment Management Group. Company insiders that have sold MEDNAX company stock in the last year include David A Clark, Dominic J Andreano, John C Pepia, Joseph M Calabro and Md Pascal J Goldschmidt. View Insider Buying and Selling for MEDNAX.

Which major investors are buying MEDNAX stock?

MD stock was bought by a variety of institutional investors in the last quarter, including P2 Capital Partners LLC, AQR Capital Management LLC, D. E. Shaw & Co. Inc., WINTON GROUP Ltd, Panagora Asset Management Inc., Acadian Asset Management LLC, IPG Investment Advisors LLC and Nuveen Asset Management LLC. View Insider Buying and Selling for MEDNAX.

How do I buy shares of MEDNAX?

Shares of MD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is MEDNAX's stock price today?

One share of MD stock can currently be purchased for approximately $23.00.

How big of a company is MEDNAX?

MEDNAX has a market capitalization of $1.94 billion and generates $3.65 billion in revenue each year. The company earns $268.62 million in net income (profit) each year or $3.51 on an earnings per share basis. MEDNAX employs 7,625 workers across the globe.View Additional Information About MEDNAX.

What is MEDNAX's official website?

The official website for MEDNAX is http://www.mednax.com/.

How can I contact MEDNAX?

MEDNAX's mailing address is 1301 CONCORD TERRACE, SUNRISE FL, 33323. The company can be reached via phone at 954-384-0175 or via email at [email protected]


MarketBeat Community Rating for MEDNAX (NYSE MD)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  454 (Vote Outperform)
Underperform Votes:  487 (Vote Underperform)
Total Votes:  941
MarketBeat's community ratings are surveys of what our community members think about MEDNAX and other stocks. Vote "Outperform" if you believe MD will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MD will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 9/22/2019 by MarketBeat.com Staff

Featured Article: Momentum Investing

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel